Alphamark Advisors Has Cut Its Enanta Pharmaceutical (ENTA) Holding; Shorts at HYUNDAI MOTOR REG S (HYMTF) Raised By 16.67%

January 15, 2018 - By Michael Collier

HYUNDAI MOTOR REG S (OTCMKTS:HYMTF) had an increase of 16.67% in short interest. HYMTF’s SI was 700 shares in January as released by FINRA. Its up 16.67% from 600 shares previously. With 800 avg volume, 1 days are for HYUNDAI MOTOR REG S (OTCMKTS:HYMTF)’s short sellers to cover HYMTF’s short positions. It closed at $42.5 lastly. It is down 0.00% since January 15, 2017 and is . It has underperformed by 16.70% the S&P500.

Alphamark Advisors Llc decreased Enanta Pharmaceutical (ENTA) stake by 22.73% reported in 2017Q3 SEC filing. Alphamark Advisors Llc sold 7,500 shares as Enanta Pharmaceutical (ENTA)’s stock rose 11.35%. The Alphamark Advisors Llc holds 25,500 shares with $1.19M value, down from 33,000 last quarter. Enanta Pharmaceutical now has $1.17 billion valuation. The stock increased 1.18% or $0.71 during the last trading session, reaching $60.98. About 75,042 shares traded. Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) has risen 40.91% since January 15, 2017 and is uptrending. It has outperformed by 24.21% the S&P500.

Hyundai Motor Company, together with its subsidiaries, makes and distributes motor vehicles and parts worldwide. The company has market cap of $27.21 billion. It operates in Vehicle, Finance, and Other divisions. It has a 7.21 P/E ratio. The firm offers cars under the Centennial/Equus, Genesis, Azera, Sonata, Sonata Turbo, i40, i40 Sedan, Elantra, Elantra Sport, i30, i30 Wagon, i30 3DR, Veloster, Veloster Turbo, Accent, Accent 5DR, ix20, i20, i20 Coupe, Elite i20, HB20, Xcent, i10, Grand i10, and Eon names, as well as IONIQ ELECTRIC, IONIQ-Hybrid, Grand Santa Fe, and ix20 names.

Analysts await Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) to report earnings on February, 14. They expect $0.04 earnings per share, up 115.38% or $0.30 from last year’s $-0.26 per share. ENTA’s profit will be $764,841 for 381.13 P/E if the $0.04 EPS becomes a reality. After $1.86 actual earnings per share reported by Enanta Pharmaceuticals, Inc. for the previous quarter, Wall Street now forecasts -97.85% negative EPS growth.

Investors sentiment increased to 1.6 in Q3 2017. Its up 0.75, from 0.85 in 2017Q2. It improved, as 9 investors sold ENTA shares while 31 reduced holdings. 16 funds opened positions while 48 raised stakes. 12.10 million shares or 2.87% more from 11.77 million shares in 2017Q2 were reported. Nationwide Fund Advsr invested 0% of its portfolio in Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA). Northern Corporation holds 0% or 195,523 shares. Qs Invsts Limited Liability Corporation has invested 0.03% in Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA). Ameriprise Fin has 143,817 shares. Ls Advsr Limited Liability holds 0.01% of its portfolio in Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) for 2,369 shares. Pnc Grp Inc Inc accumulated 0% or 170 shares. Parkside Finance Bank Tru holds 0% of its portfolio in Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) for 13 shares. Automobile Association stated it has 0% of its portfolio in Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA). Guggenheim Capital Limited Liability Corporation invested in 27,763 shares or 0% of the stock. Credit Suisse Ag holds 0% or 31,994 shares in its portfolio. Campbell And Co Invest Adviser Ltd Co holds 0.18% of its portfolio in Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) for 4,709 shares. Meeder Asset Management owns 950 shares for 0% of their portfolio. Pub Employees Retirement Sys Of Ohio has 0.01% invested in Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) for 20,644 shares. 32,167 are held by Ajo L P. New York-based Bnp Paribas Arbitrage Sa has invested 0% in Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA).

Alphamark Advisors Llc increased Janus Short Duration I stake by 11,155 shares to 104,206 valued at $5.25M in 2017Q3. It also upped Ishares Ibonds Dec 201 stake by 17,374 shares and now owns 237,887 shares. Digital Realty Trust (NYSE:DLR) was raised too.

Among 5 analysts covering Enanta Pharmaceuticals Inc (NASDAQ:ENTA), 2 have Buy rating, 1 Sell and 2 Hold. Therefore 40% are positive. Enanta Pharmaceuticals Inc had 20 analyst reports since August 7, 2015 according to SRatingsIntel. The company was downgraded on Friday, August 7 by Zacks. As per Monday, November 20, the company rating was maintained by RBC Capital Markets. Barclays Capital downgraded Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) rating on Friday, October 23. Barclays Capital has “Underweight” rating and $16 target. Robert W. Baird maintained the stock with “Hold” rating in Friday, September 15 report. As per Monday, November 20, the company rating was maintained by Robert W. Baird. As per Tuesday, January 2, the company rating was downgraded by RBC Capital Markets. On Friday, October 20 the stock rating was maintained by RBC Capital Markets with “Buy”. JMP Securities upgraded the stock to “Market Outperform” rating in Tuesday, July 11 report. The company was downgraded on Saturday, August 8 by TheStreet. On Friday, October 20 the stock rating was maintained by Robert W. Baird with “Hold”.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter:


Recent Posts